Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel
Other

Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel

Tracked across 1 events · 6 articles · First seen Jun 10, 2026 · Last active Jun 10, 2026

Sentiment
75
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 75
Business
Medexus licenses Zemcelpro for Canada
Impact: Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel (UM171 Cell Therapy) is a novel personalized cryopreserved hematopoietic stem cell transplantation product for blood cancers, which has received conditional marketing authorization in Europe and is now subject to licensing agreements for Canadian commercialization.
Jun 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.